Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Janssen reports positive clinical data for plaque psoriasis drug

Janssen reports positive clinical data for plaque psoriasis drug

4th October 2016

Janssen has announced new phase III clinical trial data that demonstrates the benefits offered by its new psoriasis therapy guselkumab.

Findings from the first of three pivotal phase III studies evaluating the subcutaneously administered anti-interleukin-23 monoclonal antibody have been reported, showing its safety and efficacy in the treatment of adults with moderate to severe plaque psoriasis.

Data from the VOYAGE 1 trial showed significantly higher proportions of patients receiving guselkumab achieved cleared/minimal disease compared with patients receiving placebo, while the drug also showed benefits compared to an established alternative.

These results were presented at the 25th European Academy of Dermatology and Venereology Congress and represented the first ever findings from a head-to-head study of an IL-23–targeted biologic therapy compared with an anti-TNF-alpha treatment.

Dr Newman Yielding, head of immunology development at Janssen's research and development division, said: "We are committed to translating scientific progress into medicines for immune diseases like psoriasis where patients are still waiting for improved outcomes and treatment experiences."

A phase II study evaluating guselkumab in the treatment of moderately to severely active psoriatic arthritis is also ongoing.

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.ADNFCR-8000103-ID-801826262-ADNFCR

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.